Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent
Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
NKTR-102 Shows 29 Percent Response in Phase II Study
New Two-Step Matching Process Increases Success of Transplants
Weak Electromagnetic Fields Can Possibly Stabilize Tumors
One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent
Neurocognitive Deficits Affect Future Adult Employment
Smoking, Drinking Factors Affect Adherence to Preventive Regimen
Two Doses of the Vaccine Cervarix Can Be As Effective As Three
HPV-Positive Women Over 30 Should Be Retested Within Two Years
Clinical Trials Approved By NCI CTEP Last Month
Nucynta ER Approved For Managing Chronic Pain In Adults
Zofran Label Change Includes Warnings of QT Prolongation
Agency Approves Two Pairs Of Drugs and Diagnostic Tests
Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?
